Navigation Links
MDNA Selects Phi Life Sciences as its First US Distribution Partner for its New Liquid Biopsy Test for Prostate Cancer
Date:11/30/2016

WEST PALM BEACH, Fla., Nov. 30, 2016 /PRNewswire/ -- MDNA Life Sciences Inc. (MDNA), the molecular diagnostics company pioneering the development of liquid biopsy tests based on the mitochondrial genome, announced today that it has entered into a license agreement with Phi Life Sciences (Phi). Under the agreement, Phi is the first US partner to distribute MDNA's proprietary liquid biopsy test for prostate cancer, the Prostate Mitomic Test (PMT™).

"We chose Phi as our first commercial partner to offer PMT™ because of its strong network within the molecular diagnostic space," said Chris Mitton, CEO of MDNA Life Sciences Inc.  "Launching PMT™ with Phi will allow us to quickly build a user base to drive market acceptance and adoption.  This valuable partnership will also help with the collection of post-market data for PMT™ to demonstrate clinical utility," he added.

PMT™ is a liquid biopsy test for the early detection of high-grade prostate cancer in advance of biopsy.  It is intended for use in men with clinical suspicion of prostate cancer to determine who is likely to have high-grade cancer that may require immediate intervention.  PMT's negative predictive value will also be useful in identifying cases that can safely delay or forego immediate biopsy.  Current clinical practice using PSA as a first-line screening tool results in many unnecessary biopsies.   PMT™ will significantly aid clinicians in differentiating between men who will benefit from immediate biopsy from those who will not, thus avoiding a costly and invasive procedure.  

"We are excited to be the first commercial partner to have access to MDNA's advanced liquid-biopsy test for prostate cancer. PMT™ is a valuable addition to our test portfolio and aligns well with our vision to empower physicians to deliver more precise clinical treatments and diagnoses.  PMT™ is unique in the area of prostate cancer diagnostics as it does not rely on the use of PSA or PSA variants, providing our clinicians the ability to evaluate a patient's risk with a new molecular data point," said Sawan Hurst, Chief Executive Officer of Phi Life Sciences.  

About Phi Life Sciences (Phi)
Phi is a commercialization catalyst for innovation and intends to become the leader in integrated healthcare solutions by providing best-in-class clinical products supported by robust analytics. Phi's mission is to revolutionize traditional medical practice through the application of a broad based suite of molecular diagnostic tests.  For more information visit  http://www.philifesciences.com 

About MDNA Life Sciences Inc.
MDNA Life Sciences, Inc. is leading the development of molecular diagnostic tests using its proprietary Mitomic Technology™ platform that exploits the unique biological characteristics of mitochondrial DNA, a highly attractive and effective system for biomarker discovery, early disease detection, monitoring, risk assessment and therapeutic targeting. This innovative platform has led to the discovery of numerous novel and proprietary biomarkers for a multitude of cancers and other diseases.  The Company is applying its expertise in mitochondrial genomics to develop an extensive and proprietary portfolio of blood-based molecular tests for conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection.  PMT™ is MDNA's second Mitomic test for prostate cancer with market-leading assay performance, the first being a post-biopsy tissue-based test.  A test for endometriosis is being readied for launch in the first half of 2017, and further tests for other cancers are in the pipeline with tests for ovarian and lung cancer set to be launched by 2018.  For more information visit www.mdnalifesciences.com

For further information, please contact:
Christopher Mitton
844-321-6362
c.mitton@mdnalifesciences.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mdna-selects-phi-life-sciences-as-its-first-us-distribution-partner-for-its-new-liquid-biopsy-test-for-prostate-cancer-300369924.html


'/>"/>
SOURCE MDNA Life Sciences Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Foremost Global Medical Device Manufacturer Selects ValGenesis Validation Lifecycle Management System to Streamline the Validation Process across Global Manufacturing Sites
2. Lincolnshire Health and Care Selects InterSystems HealthShare to Transform Patient Care for the Region
3. East Tennessee Health Information Network Selects IMAT Solutions for Big Data Management after Extensive, Multi-year Search
4. Connecticut Childrens Medical Center Selects Fujifilm Synapse VNA
5. Episcopal Communities and Services (ECS) selects SONIFI Healths Senior Living Engagement System to further enrich the resident lifestyle
6. The University of Kansas Hospital Selects Omnicell Automation Solutions to Advance Patient Safety and Efficiency
7. Cognition Life Science Selects Smart Science Laboratories for Production
8. CIOReview Selects Psyche Systems for 50 Most Promising Healthcare Solution Providers 2015
9. Saint Marys Regional Medical Center in Reno, Nevada selects Vincaris Lightspeed Valet for Surgeons to Create ICD-10 Specific Operative Reports
10. RightEye Selects SMI Eye Trackers to Use in Eye Tracking-Based Vision Tests
11. UKs National Health Service Selects 20 Varian TrueBeam Systems for Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):